Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona.

The CVGBM vaccine encodes multiple molecular features derived from tumor-associated antigens, all of which were judged to be potentially relevant in glioblastoma.

After reporting her group’s findings to the ESMO Barcelona meeting, first author Ghazaleh Tabatabai, MD, PhD, a neurologist, Professor of Neuro-Oncology, and Chair of the Department of Neurology and Interdisciplinary Neuro-Oncology at the University Hospital, Tübingen, Germany, talked about the findings with Oncology Times reporter Peter Goodwin.